{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8190","upperLimit":"20000","value":"10800"},{"groupId":"OG001","lowerLimit":"21100","upperLimit":"30700","value":"25300"},{"groupId":"OG002","lowerLimit":"5660","upperLimit":"33900","value":"25700"},{"groupId":"OG003","lowerLimit":"45800","upperLimit":"72000","value":"58900"},{"groupId":"OG004","lowerLimit":"81200","upperLimit":"115000","value":"87600"},{"groupId":"OG007","lowerLimit":"277000","upperLimit":"277000","value":"277000"},{"groupId":"OG009","lowerLimit":"385000","upperLimit":"385000","value":"385000"},{"groupId":"OG010","lowerLimit":"11500","upperLimit":"74100","value":"34600"},{"groupId":"OG011","lowerLimit":"51700","upperLimit":"173000","value":"81000"},{"groupId":"OG012","lowerLimit":"51400","upperLimit":"258000","value":"122000"},{"groupId":"OG013","lowerLimit":"0.00","upperLimit":"126000","value":"63000"},{"groupId":"OG014","lowerLimit":"73600","upperLimit":"508000","value":"99300"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"5"},{"groupId":"OG011","value":"5"},{"groupId":"OG012","value":"3"},{"groupId":"OG013","value":"2"},{"groupId":"OG014","value":"6"}],"units":"Participants"}],"title":"Cycle 1 day 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"540000","upperLimit":"540000","value":"540000"},{"groupId":"OG001","lowerLimit":"119000","upperLimit":"217000","value":"124000"},{"groupId":"OG002","lowerLimit":"225000","upperLimit":"242000","value":"234000"},{"groupId":"OG003","lowerLimit":"202000","upperLimit":"202000","value":"202000"},{"groupId":"OG004","lowerLimit":"379000","upperLimit":"491000","value":"435000"},{"groupId":"OG006","lowerLimit":"20100","upperLimit":"249000","value":"134000"},{"groupId":"OG007","lowerLimit":"990000","upperLimit":"990000","value":"990000"},{"groupId":"OG008","lowerLimit":"352000","upperLimit":"684000","value":"518000"},{"groupId":"OG009","lowerLimit":"293000","upperLimit":"838000","value":"473000"},{"groupId":"OG010","lowerLimit":"59100","upperLimit":"805000","value":"432000"},{"groupId":"OG011","lowerLimit":"97800","upperLimit":"313000","value":"197000"},{"groupId":"OG013","lowerLimit":"121000","upperLimit":"121000","value":"121000"},{"groupId":"OG014","lowerLimit":"175000","upperLimit":"284000","value":"217000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"2"},{"groupId":"OG011","value":"4"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"1"},{"groupId":"OG014","value":"3"}],"units":"Participants"}],"title":"Cycle 1 day 9"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"5"},{"groupId":"OG011","value":"5"},{"groupId":"OG012","value":"3"},{"groupId":"OG013","value":"2"},{"groupId":"OG014","value":"6"}],"units":"Participants"}],"description":"Plasma concentrations of AMG 176 were determined using a validated assay. Noncompartmental analysis was performed for estimation of PK parameters. Concentrations below the LLOQ of 5.00 ng/mL were set to zero before data analysis.","dispersionType":"Full Range","groups":[{"description":"Participants with MM received AMG 176 Dose A BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG000","title":"Part 1A Cohort 1 (MM): AMG 176 Dose A BIW"},{"description":"Participants with MM received AMG 176 Dose B IV BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG001","title":"Part 1A Cohort 2 (MM): AMG 176 Dose B BIW"},{"description":"Participants with MM received AMG 176 Dose C BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG002","title":"Part 1A Cohort 3 (MM): AMG 176 Dose C BIW"},{"description":"Participants with MM received AMG 176 Dose D BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG003","title":"Part 1A Cohort 4 (MM): AMG 176 Dose D BIW"},{"description":"Participants with MM received AMG 176 Dose E BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG004","title":"Part 1A Cohort 5 (MM): AMG 176 Dose E BIW"},{"description":"Participants with MM received AMG 176 Dose G BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG005","title":"Part 1A Cohort 6 (MM): AMG 176 Dose G BIW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose F BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG006","title":"Part 1A Cohort 7 (MM): AMG 176 Dose E Then Dose F BIW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose G BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG007","title":"Part 1A Cohort 8 (MM): AMG 176 Dose E Then Dose G BIW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose H BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG008","title":"Part 1A Cohort 9 (MM): AMG 176 Dose E Then Dose H BIW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose I BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG009","title":"Part 1A Cohort 10 (MM): AMG 176 Dose E Then Dose I BIW"},{"description":"Participants with AML received AMG 176 Dose D BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG010","title":"Part 3 Cohort 1 (AML): AMG 176 Dose D BIW"},{"description":"Participants with AML received AMG 176 Dose E BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG011","title":"Part 3 Cohort 2 (AML): AMG 176 Dose E BIW"},{"description":"Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose F BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG012","title":"Part 3 Cohort 3 (AML): AMG 176 Dose E Then Dose F BIW"},{"description":"Participants with AML received AMG 176 Dose E BIW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\\^2 azacitidine SC or IV QD for 7 days in week 1.","id":"OG013","title":"Part 4 Cohort 5A (AML): AMG 176 Dose E BIW + Azacitidine"},{"description":"Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose G BIW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\\^2 azacitidine SC or IV QD for 7 days in week 1.","id":"OG014","title":"Part 4 Cohort 5B (AML): AMG 176 Dose E the Dose G BIW + Azacitidine"}],"paramType":"MEDIAN","populationDescription":"The PK analysis set included all participants who had received at least 1 dose of AMG 176 and had at least 1 PK sample collected. AUC0-144 was pre-specified in Parts 1A, 3A (Cohorts 1, 2, and 3) and 4 (Cohorts 5A and 5B) and participants with data available at each time point are presented.","reportingStatus":"POSTED","timeFrame":"Parts 1A, 3A, and 4: Cycle 1 day 2 pre, EOI, 1, 2, 3, 5, and 7 hrs EOI, cycle 1 day 9 pre and EOI","title":"AUC From Time 0 to 144 Hours (AUC0-144) of AMG 176 (Parts 1A, 3A [Cohorts 1, 2, and 3], and 4 [Cohorts 5A and 5B])","type":"PRIMARY","unitOfMeasure":"hour*ng/mL"}